Immix Biopharma Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
/ 
Frequently asked questions
To buy Immix Biopharma Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Immix Biopharma Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Immix Biopharma Inc. is IMMX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Immix Biopharma Inc. has its primary listing on NASDAQ (Small cap). You can trade Immix Biopharma Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Immix Biopharma Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Immix Biopharma Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Immix Biopharma Inc..